# Orchestra BioMed corporate developments > Live situation record from CLSTR: https://clstr.news/situations/orchestra-biomed-corporate-developments > Updated: 2026-09-01T00:00:00.000Z. Sources: 4. Developments: 2. Orchestra BioMed Holdings, Inc. has moved from reporting financial forecasts and insider trading activity toward presenting its clinical developments at investor conferences. In early August, the company prepared to release its second-quarter 2026 results, with analysts anticipating a loss of $0.35 per share. During this period, insider Darren Sherman sold 15,000 shares under a pre-arranged trading plan. By September, the company announced its participation in the H. C. Wainwright 28th Annual Global Investment Conference. Orchestra BioMed intends to discuss two medical-device programs currently in pivotal clinical trials: Atrioventricular Interval Modulation Therapy (AVIM Therapy) for hypertension and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease. Both programs have received FDA Breakthrough Device Designations. ## Timeline ### 2026-09-01: Orchestra BioMed and Immunocore announce investor conference appearances Biotechnology companies Orchestra BioMed and Immunocore are scheduled to present their clinical developments and investment cases at several global healthcare and investment conferences in September. 4 sources. https://clstr.news/cluster/orchestra-biomed-and-immunocore-announce-investor-conference-appearances ### 2026-08-03: Orchestra BioMed Announces Q2 2026 Earnings Forecast and Reports Insider Share Sale Orchestra BioMed (OBIO) is set to report Q2 2026 earnings—forecasted at a $0.35 loss per share on $0.138 M revenue—while insider Darren Sherman sold 15,000 shares, reducing his holding by about 1.3%. 4 sources. https://clstr.news/cluster/telephone-and-data-systems-and-life360-set-q2-2026-earnings-forecasts --- Cite as: Orchestra BioMed corporate developments. CLSTR, https://clstr.news/situations/orchestra-biomed-corporate-developments